ChemoCentryx, Inc. (CCXI)
| Market Cap | 3.25B |
| Revenue (ttm) | 64.89M |
| Net Income (ttm) | -55.36M |
| Shares Out | 65.69M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $46.54 |
| Previous Close | $47.15 |
| Change ($) | -0.61 |
| Change (%) | -1.29% |
| Day's Open | 47.74 |
| Day's Range | 46.38 - 48.58 |
| Day's Volume | 314,747 |
| 52-Week Range | 44.68 - 70.29 |
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first hal...
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET....
ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company's Executive Vice President and Chief Financi...
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated ...
MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after...
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan's effec...
MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.
MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from the ACCOL...
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upco...
ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), which miss...
-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authorizati...
-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTAIN...
ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Med...
MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close o...
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at ...
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Final Trades: AT&T, Jumia Technologies, Chemocentryx, General Motors
The “Halftime Report” traders give their top picks to watch for the second half.
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration ...
MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H...
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis -- -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total cash, cash...
MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market clos...
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Admini...
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 i...
MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentry...
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at ...
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with...
ChemoCentryx: Avacopan's Attractive Value Proposition
MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a ...
ChemoCentryx, Inc. (CCXI) CEO Dr.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.
ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
About CCXI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The... [Read more...]
| Industry Biotechnology | IPO Date Feb 8, 2012 |
| CEO Thomas Schall | Employees 133 |
| Stock Exchange NASDAQ | Ticker Symbol CCXI |
Financial Performance
In 2020, ChemoCentryx's revenue was $64.89 million, an increase of 79.61% compared to the previous year's $36.13 million. Losses were -$55.36 million, -0.24% less than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 88.88, which is an increase of 90.98% from the latest price.